Teva launches generic Biaxin, then puts sales on hold

New York, June 27 - Teva Pharmaceutical Industries Ltd. said it launched its generic Biaxin (Clarithromycin) XL Filmtabs - then put sales on hold.

The product was launched Friday after the U.S. Court of Appeals for the Federal Circuit on Thursday vacated a June 2005 ruling grating Abbott's motion for a preliminary injunction related to the product.

But on Monday Abbott filed an emergency motion in the U.S. District Court for the Northern District of Illinois, where the patent infringement case is pending with a trial scheduled for March 2007, to enjoin Teva from further sales of the product pending additional appeals.

In order to permit the motion to be presented to the judge most familiar with the case, Abbott agreed to a briefing schedule concluding on June 29 and Teva agreed to refrain from further sales of the product pending the outcome of the motion.

Teva is a Jerusalem, Israel, based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.